12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Company News  |  Deals

AxoGen Inc., PDL BioPharma deal

PDL purchased high single-digit royalties on AxoGen's product revenues over the next eight years for $20.8 million in cash. The deal includes minimum payments beginning in 4Q14. PDL has the right to require AxoGen to repurchase...

Read the full 159 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >